Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PTEN mut TP53 mut |
| Therapy | Dordaviprone + Navitoclax |
| Indication/Tumor Type | glioblastoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN mut TP53 mut | glioblastoma | sensitive | Dordaviprone + Navitoclax | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Modeyso (dordaviprone) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387). | 26474387 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26474387) | TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. | Full reference... |